### CDC Recommends Additional COVID-19 Vaccine Doses for High-Risk Groups

The Centers for Disease Control and Prevention (CDC) has issued new guidance for adults aged 65 and older, as well as individuals with weakened immune systems, recommending they receive two doses of the newly updated COVID-19 vaccine. This is a significant update aimed at enhancing protection against the virus, particularly for those most vulnerable to severe illness.

According to the CDC, these high-risk groups should seek their second dose at least six months after receiving their first. The guidelines, announced on October 23, also suggest that people with moderate to severe immunosuppression may benefit from receiving three or more doses. Consultation with a medical provider can help determine whether multiple doses would be advantageous.

"The recommendation acknowledges the increased risk of severe disease from COVID-19 in older adults and those who are immunocompromised," the CDC stated. Unlike the seasonal flu, COVID-19 circulates throughout the year, making it crucial for certain individuals to receive more frequent boosts to their immunity.

The CDC emphasized that getting the recommended 2024-2025 COVID-19 vaccines can bolster defense against the virus variants causing most infections and hospitalizations in the United States. Additionally, vaccination significantly reduces the likelihood of experiencing Long COVID.

The updated vaccination guidelines extend to everyone aged 6 months and older, suggesting at least one dose of a 2024-2025 COVID-19 vaccine. Three vaccines are currently available: Pfizer-BioNTech, Moderna, and Novavax. While Pfizer and Moderna vaccines use mRNA technology, Novavax employs virus proteins and an immune-boosting substance. Notably, the Novavax vaccine is approved only for those aged 12 and up, whereas the other two are suitable for children as young as 6 months.

For younger children, the number of recommended doses—ranging from one to three—varies depending on the vaccine brand and their previous COVID-19 vaccination history. Detailed guidelines are accessible on the CDC website.

The 2024-2025 vaccines have been updated to address new variants of the coronavirus. The Pfizer and Moderna vaccines target the KP.2 variant of the omicron family, which gained prominence in June. Novavax focuses on an earlier variant, JN.1, which KP.2 has since surpassed. Emerging variants, including KP.3.1.1, have appeared since summer, yet laboratory tests indicate that all three vaccines generate antibodies effective against a broad spectrum of JN.1 descendants, such as KP.2 and KP.3.

The CDC's updated recommendations aim to ensure that high-risk groups receive adequate protection throughout the year. For more information on where to get a COVID-19 vaccine, visit the CDC website.

This article serves informational purposes and does not provide medical advice.